27,780 Alzheimer's and dementia studies in plain English, each scored out of 100.
Alzheimer’s disease pathology and cognitive outcomes frequently diverge, yet current single-axis definitions cannot identify resilient (high pathology, preserved cognition) and resistant (high risk, low pathology) subgroups reliably at scale, obscuring the mechanisms that uncouple pathological burden from cognitive decline. 2 key findings →
Participants: 1,009 Evidence: moderate
Full summary, score breakdown and related studies → Original source
Residualized WMH T1w/T2w-FLAIR ratio captures lesion-specific microstructural variation missed by volumetric measures, consistent with vascular-gliotic injury in VD and coexisting amyloid-linked demyelination in AD. 4 key findings →
Design: cross-sectional Participants: 71 Evidence: moderate
Full summary, score breakdown and related studies → Original source
Genetic risks were primarily associated with Aβ and tau pathology, clinical risks with neurodegeneration, and SDoH risks with cognition, suggesting that risk factors exert differential effects on AD pathophysiology. 5 key findings →
Design: cohort study Participants: 2,276 Evidence: moderate
Full summary, score breakdown and related studies → Original source
Semi-supervised multimodal fusion improves prediction and reveals interpretable imaging patterns that predict APOE4 and clinical diagnoses better than traditional approaches. 2 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
Shorter sleep duration and greater REM sleep variability may index early AD-related brain changes, warranting longitudinal studies to establish their prognostic significance. 2 key findings →
Design: longitudinal study Evidence: high
Full summary, score breakdown and related studies → Original source
Neuropsychiatric symptoms (NPS) are highly prevalent in Mild Cognitive Impairment (MCI), conceptualized as an intermediate clinical state between normal aging and dementia. 4 key findings →
Design: longitudinal study Evidence: moderate
Full summary, score breakdown and related studies → Original source
This study investigated volumetric MRI differences of the thalamic nuclei in asymptomatic young adult C9orf72 expansion carriers compared to non-carriers, and examined spatial associations with normative thalamic transcriptomics from 8 weeks post-conception through middle age. 3 key findings →
Participants: 72 Evidence: low
Full summary, score breakdown and related studies → Original source
The basal forebrain is an early site of pathology in Alzheimer’s disease (AD). 3 key findings →
Design: longitudinal study Participants: 116 Evidence: moderate
Full summary, score breakdown and related studies → Original source
In this cohort, APOE ε4 carrier status was related to disease severity at baseline rather than to the rate of cognitive decline over 80 weeks. 3 key findings →
Design: clinical trial Participants: 370 Evidence: moderate
Full summary, score breakdown and related studies → Original source
Amyloid plaques, one of the defining features of Alzheimer’s disease, are associated with synapse loss and accumulation of pathological tau in dystrophic neurites and reactive glia in their immediate vicinity. 3 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
The cost-effectiveness of ATTs is strongly influenced by the waning of the treatment effect. 1 key finding →
Evidence: moderate
Full summary, score breakdown and related studies → Original source
Biases in cognitive/functional screening tests may disproportionately exclude ethnoracial minorities in AD prevention trials. 1 key finding →
Participants: 6,669 Evidence: low
Full summary, score breakdown and related studies → Original source
NODDI-derived ODI is associated with tau PET signal, even in preclinical disease and may discriminate individuals with-and without tau beyond the MTL. 3 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
These therapies require complex diagnostic workup and safety monitoring, raising significant budget impact concerns for healthcare payers. 2 key findings →
Participants: 11,568 Evidence: low
Full summary, score breakdown and related studies → Original source
The overall incidence of any ARIA was 25.2%, with ARIA-H occurring in 22.4% of patients and ARIA-E in 12.2%. 3 key findings →
Design: cohort study Participants: 468 Evidence: moderate
Full summary, score breakdown and related studies → Original source
MCH-Guard offers a flexible clinical decision-support tool for optimizing spontaneous MCH & ARIA surveillance. 1 key finding →
Design: longitudinal study Participants: 813 Evidence: moderate
Full summary, score breakdown and related studies → Original source
Temporal imaging variables may provide independent prognostic information beyond baseline risk, supporting a dynamic model of haemorrhagic risk in Alzheimer’s disease. 2 key findings →
Participants: 1,069 Evidence: low
Full summary, score breakdown and related studies → Original source
We trained a self-configuring nnU-Net model for CMB segmentation in a hetero-geneous multicenter sample ( n =264), including 1.5T and 3T field strengths, SWI and T2*-GRE sequences, and community and clinical cohorts. 1 key finding →
Participants: 264 Evidence: low
Full summary, score breakdown and related studies → Original source
Our study examined the safety and tolerability of centralized lecanemab administration across a widely distributed region and suggests that use of distributed infusion sites increases access to disease-modifying treatment without significant increase in risk. 2 key findings →
Participants: 70 Evidence: low
Full summary, score breakdown and related studies → Original source
The complete absence of ARIA distinguishes XPro1595 from amyloid-targeting therapies and supports its potential for use in combination strategies and potentially for those at a higher risk of ARIA. 5 key findings →
Design: clinical trial Evidence: high
Full summary, score breakdown and related studies → Original source
SGLT2 inhibitors and GLP-1 receptor agonists have the greatest effect on cognition in T2DM, and the multi-component exercise as the most effective lifestyle component. 3 key findings →
Design: meta-analysis Participants: 213,604 Evidence: high
Full summary, score breakdown and related studies → Original source
We describe the demographic and clinical characteristics of new initiators of GLP-1RAs compared with initiators of alternative therapies, including sodium-glucose cotransporter-2 inhibitors (SGLT2i) and dipeptidyl peptidase-4 inhibitors (DPP-4i). 5 key findings →
Design: retrospective cohort Participants: 58,754 Evidence: moderate
Full summary, score breakdown and related studies → Original source
These findings reinforce the potential of GLP-1RAs and SGLT2i as therapeutic options to slow cognitive decline in DM2, possibly depending on glycemic control and central modulation. 5 key findings →
Design: cohort study Participants: 12 Evidence: high
Full summary, score breakdown and related studies → Original source
Among adults with obesity or overweight with a weight related condition, there was no difference in the risk of PD or Parkinsonian disorders between GLP-1 RA users and non-users. 4 key findings →
Design: cohort study Participants: 11,683 Evidence: moderate
Full summary, score breakdown and related studies → Original source
Four distinct subtypes were identified: I low-risk healthy aging, II behavioral/social vulnerability, III cardiometabolic–depressive multimorbidity, and IV mixed social-medical vulnerability profiles. 5 key findings →
Design: cohort study Evidence: moderate
Full summary, score breakdown and related studies → Original source
Free full text links and the Full text may need a subscription label come from Unpaywall, Europe PMC and OpenAlex records of free copies, checked 10 Oct 2026. A study with neither is unknown, not paywalled. Show only studies that are free to read
This is alzhub's own score. It is not an official metric, not an impact factor, and no journal, publisher or ranking body endorses it. We built it so that a reader who is not a scientist can tell a landmark trial from a conference abstract without having to already know the difference. Every point comes from one of 20 components, all of them printed on the study itself, so you can disagree with our arithmetic rather than having to trust the total.
Journals are placed in ordered tiers, never given a numeric impact factor — we could not verify current impact factors from a source we control, and an invented one would be worse than none. Tier 1 is the top-tier general journals (NEJM, The Lancet, JAMA, Nature, Science, Nature Medicine); tier 2 is the leading specialty journals; tier 3 is every other peer-reviewed journal. A separate part scores how much the journal's own papers are cited, which tells the tier-3 journals apart.
Two rules we don't bend. First, we never fill in a missing value: if a record does not state a sample size or a design, that component scores zero, and if we simply have no data for a part, such as a citation count, that part is left out and the study is scored on the parts we could check. The study card says which. Second, anything that is not a peer-reviewed article is capped at 16/100 and carries a warning chip — so a conference abstract or a company press release can never outrank a peer-reviewed paper, no matter how good it looks.
We rank a rigorous null result — a good trial showing that something does not work — above an early positive finding. Someone deciding whether to buy a supplement is served by that, and the rigour is already counted by the design and journal components.
The score is computed from the published data alone and is reproducible: the same file always yields the same numbers.
See the whole rubric drawn out → — four charts covering all 27,780 studies: how the scores are spread and where the cap bites, which of the 20 components the library is strong and weak on, which subjects rest on stronger evidence, and what kinds of study each subject is actually built from.
This is a large sample of the Alzheimer's literature, not an exhaustive index of it. It holds 27,780 records, built mostly from automated pulls of Europe PMC (61.1% of the library) and OpenAlex (18.3%), plus smaller pulls from PubMed, Crossref and medRxiv. If a study, a drug, or a finding isn't here, that is not evidence it doesn't exist in the literature — it may simply not have been pulled in yet.
1,034 records (3.7% of the library) are not peer-reviewed — 962 of those are preprints posted before any journal review, and the rest are conference abstracts, regulatory notices and reports. Every study card on this page states its status plainly, and the score above is capped for anything that isn't a peer-reviewed article.
See the full, machine-readable breakdown of this library's coverage →